BioNTech (BNTX) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
BioNTech (BNTX) publicó su última previsión de agosto 4, 2026 para fiscal year 2026. La compañía estimó ingresos en un rango de $1.86B - $2.21B para el período.
En comparación con la previsión anterior, BioNTech reducido redujo su previsión de ingresos desde un rango anterior de $2.33B - $2.68B.
BioNTech ha emitido 13 actualizaciones de orientación entre el enero 9, 2024 y el agosto 4, 2026. During this period, the company raised its outlook 1 time and lowered it 6 times, providing investors with insight into management's evolving expectations.
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-2.34 | $-2.52 | $-0.47 | $0.75 |
| Actual | $-2.58 | $-2.28 | $-0.38 | $-0.14 |
| Surprise | -10.3% | +9.52% | +19.1% | -118.7% |
| Revenue | ||||
| Estimate | $182.0M | $214.6M | $889.5M | $1.19B |
| Actual | $122.8M | $138.0M | $1.06B | $1.78B |
| Surprise | -32.6% | -35.7% | +18.7% | +49.2% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E |
|---|---|---|---|
| Earnings Per Share (Non-GAAP) | |||
| Consensus | $0.91 | $-1.34 | $-2.66 |
| Revenue | |||
| Consensus | $1.21B | $688.4M | — |
| Trimestre Fiscal | Fecha reportada | EPS real | EPS estimado | Sorpresa % |
|---|---|---|---|---|
| Q2 | Aug 4, 2026 | $-2.58 | $-2.34 | -10.3 % |
| Q1 | May 5, 2026 | $-2.28 | $-2.52 | 9.52 % |
| Q4 | Mar 10, 2026 | $-0.38 | $-0.47 | 19.1 % |
| Q3 | Nov 3, 2025 | $-0.14 | $0.75 | -118.7 % |
| Trimestre Fiscal | Fecha reportada | Ingresos reales | Ingresos estimados | Sorpresa % |
|---|---|---|---|---|
| Q2 | Aug 4, 2026 | $122.77M | $182.02M | -32.6 % |
| Q1 | May 5, 2026 | $138.00M | $214.62M | -35.7 % |
| Q4 | Mar 10, 2026 | $1.06B | $889.48M | 18.7 % |
| Q3 | Nov 3, 2025 | $1.78B | $1.19B | 49.2 % |